Coherus BioSciences Announces New Employment Inducement Grants
November 20 2020 - 4:01PM
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:
CHRS), today announced that effective November 19, 2020, the
compensation committee of the Company’s board of directors granted
options to purchase an aggregate of 140,500 shares of the common
stock of the Company to 10 newly hired non-officer employees, with
a per share exercise price of $17.92, the closing trading price on
the grant date.
The stock options were granted pursuant to the Coherus
BioSciences, Inc. 2016 Employment Commencement Incentive Plan,
which was approved by the Company’s board of directors in June 2016
under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity
grants to induce new employees to enter into employment with the
Company.
About Coherus
BioSciences, Inc.
Coherus is a leading biosimilar company that develops and
commercializes its own high-quality therapeutics as well as those
of others seeking capable access to the United States market.
Biosimilars are intended for use in place of existing, branded
biologics to treat a range of chronic and often life-threatening
diseases, with the potential to reduce costs and expand patient
access. Composed of a team of proven industry veterans with
world-class expertise in process science, analytical
characterization, protein production, sales and marketing,
clinical-regulatory development and commercialization, Coherus is
positioned as a leader in the global biosimilar marketplace.
Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the United
States and is advancing additional product candidates including
CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis®
(ranibizumab) biosimilar, Innovent’s Avastin® (bevacizumab)
biosimilar towards commercialization, as well as CHS-2020, an
Eylea® (aflibercept) biosimilar. For additional information, please
visit www.coherus.com.
Contact
David S. ArringtonInvestor Relations & Corporate
AffairsCoherus BioSciences, Inc.darrington@coherus.com+1 (650)
395-0196
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024